Sarcoma Clinical Trial
Official title:
A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation
Verified date | November 2017 |
Source | University of Michigan Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor, can generally be
effectively treated with a combination of surgery, radiation and chemotherapy. However,
patients with metastatic or relapsed disease have a very poor prognosis.
New approaches to the management of these difficult groups of patients are needed. There is
evidence to suggest that solid tumors may be good candidates for immunotherapy approaches. In
fact, recent experimental evidence indicates that the period of lymphopenia that occurs after
stem cell transplant may be an opportune time to use an immunotherapy treatment approach. In
light of the very poor prognosis of young patients with advanced solid tumors, this treatment
approach warrants further investigation.
Status | Completed |
Enrollment | 16 |
Est. completion date | June 2010 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 30 Years |
Eligibility |
Eligibility Inclusion Criteria: To participate in this study, it is necessary to collect sufficient tumor and peripheral blood stem cells to both develop the vaccine and perform the autologous stem cell transplant. Patients who also have previously had tumor or stem cells collected, which are available and sufficient for this study, are eligible to participate as study subjects. 1. Patients must have a histologically verified diagnosis of neuroblastoma, Wilm's tumor, or sarcoma, including rhabdomyosarcoma, a Ewing's sarcoma family tumor (ES, PNET), synovial sarcoma, fibrosarcoma, or desmoplastic round cell tumor. and must meet one of the following criteria: 1. have metastatic disease at diagnosis 2. have never achieved complete remission following frontline standard therapy 3. have relapsed after receiving standard therapy 2. Patients must have been < 30 years of age at the time of original diagnosis. 3. Patients must have a source of tumor tissue from which approximately 1 gram of viable tumor can be obtained for vaccine development. 4. Patients must have a good performance status (>70% by Lansky or Karnofsky scales). 5. Patients must have a life expectancy of at least 16 weeks. 6. Females of child-bearing age (>= 12 years old) must have a negative pregnancy test. Patients may enroll on this study at various points in their treatment including diagnosis, recurrence, or just prior to initiation of study mandated transplant therapy. Because patients may enter this study prior to completion of retransplant treatments, the below criteria must be met only to proceed to the high dose chemotherapy and autologous stem cell transplant part of this study. These criteria are not a requirement to enter this study in order to collect tumor or peripheral blood stem cells. 7. Patients must have achieved complete response or very good partial response(>= 90% decrease in tumor volume) before proceeding to transplant. For patients enrolling on this study just prior to transplant a VGPR or CR must be achieved to be eligible. 8. Patients may have undergone prior autologous peripheral blood stem cell transplantation, provided at least 12 months have elapsed prior to entry on this study. 9. Patients must have had a successful peripheral blood stem cell collection, with cryopreservation of PBSCs for both engraftment and for generation of dendritic cells. 10. Adequate baseline organ function must be present: hematologic parameters (not applicable if bone marrow is involved with tumor): 1. ANC > 500/mm3 2. platelet count > 50,000/mm3 3. serum creatinine < 1.5x upper limit of normal for age 4. serum hepatic transaminases (AST, ALT) < 3x upper limit of normal 5. serum bilirubin < 1.5x upper limit of normal 6. cardiac echocardiogram with either SF > 27% or EF > 50%. A comparable EF on a MUGA scan will also meet eligibility criteria. 11. Give or obtain informed consent Exclusion Criteria: 1. Patients who have received prior antitumor vaccines are ineligible 2. Patients who meet the response criteria but progress prior to study enrollment are ineligible 3. Patients with known autoimmune diseases or conditions are ineligible 4. Patients with HIV infection, AIDS, hepatitis B surface antigen positivity, ongoing bleeding, or any significant uncontrolled medical or psychiatric illness are ineligible. 5. Patients under treatment for infection must cleared by BMT physician prior to enrollment. 6. Patients who are pregnant or nursing are ineligible 7. Prior allogenic transplant |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan, Department of Surgery, Pediatric Section | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
University of Michigan Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To estimate the rate of immune response of this immunotherapy treatment | 70 days | ||
Secondary | To correlate and characterize the immune response to the clinical response. | three years | ||
Secondary | To define immunologic endpoints that can serve as surrogates of clinical response. | three years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |